Behandling af synstruende diabetisk retinopati

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.

OriginalsprogDansk
ArtikelnummerV11170870
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer7
ISSN0041-5782
StatusUdgivet - 2019

Fingeraftryk

Diabetic Retinopathy
Vascular Endothelial Growth Factor A

Emneord

  • Angiogenesis Inhibitors/administration & dosage
  • Anti-Inflammatory Agents/administration & dosage
  • Diabetes Mellitus, Type 1/complications
  • Diabetes Mellitus, Type 2/complications
  • Diabetic Retinopathy/drug therapy
  • Humans
  • Intravitreal Injections
  • Laser Coagulation
  • Macular Edema/drug therapy

Citer dette

@article{90d68b765d4b4a85b4768f31f640f348,
title = "Behandling af synstruende diabetisk retinopati",
abstract = "In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.",
keywords = "Angiogenesis Inhibitors/administration & dosage, Anti-Inflammatory Agents/administration & dosage, Diabetes Mellitus, Type 1/complications, Diabetes Mellitus, Type 2/complications, Diabetic Retinopathy/drug therapy, Humans, Intravitreal Injections, Laser Coagulation, Macular Edema/drug therapy",
author = "Jakob Grauslund",
year = "2019",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "7",

}

Behandling af synstruende diabetisk retinopati. / Grauslund, Jakob.

I: Ugeskrift for Laeger, Bind 181, Nr. 7, V11170870, 2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Behandling af synstruende diabetisk retinopati

AU - Grauslund, Jakob

PY - 2019

Y1 - 2019

N2 - In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.

AB - In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.

KW - Angiogenesis Inhibitors/administration & dosage

KW - Anti-Inflammatory Agents/administration & dosage

KW - Diabetes Mellitus, Type 1/complications

KW - Diabetes Mellitus, Type 2/complications

KW - Diabetic Retinopathy/drug therapy

KW - Humans

KW - Intravitreal Injections

KW - Laser Coagulation

KW - Macular Edema/drug therapy

M3 - Tidsskriftartikel

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 7

M1 - V11170870

ER -